Lilly to sell Zepbound on LillyDirect; New Purdue Pharma settlement reached; Sarepta in flux after second patient death in gene therapy trial.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Innovent completes first patient dosing in seventh phase 3 trial (GLORY-OSA) of mazdutide in China with moderate-to-severe OSA & obesity: San Francisco, US Tuesday, June 17, 2025, ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Retirement dreams often hinge on a robust portfolio, with $1 million as a coveted benchmark for financial security. Achieving ...